Drug intelligence / Profile preview

AIP 306

Development stage: Preclinical
Lead developer: AIP
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

AIP 306 is a preclinical-stage therapeutic radiopharmaceutical being developed by Advanced Innovative Partners (AIP) for the treatment of solid tumors. As a targeted radionuclide therapy, it is designed to deliver ionizing radiation directly to cancer cells by utilizing a targeting ligand, thereby inducing DNA damage and cell death while minimizing exposure to healthy tissues. The specific molecular target and radioactive isotope for AIP 306 have not been publicly disclosed in the company's pipeline documentation.

Beyond the preview

Go deeper on AIP 306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIP 306.

Explore the full profile